About this trial
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.
Eligibility criteria
Qualifiers
Hemoglobin A1C between 5.7 and 6.4
Body mass index between 27 and 45
Disqualifiers
Diabetes
Chronic use of any antidiabetic medications
Any unstable medical condition
Use of steroids or daily use of NSAIDS
Trial design
Treatments tested in this trial
- Mirabegron 50 MG
- Tadalafil 10 MG
- Placebo
Treatment groups
Sponsors and collaborators
Philip Kern
Lead sponsor
University of Kentucky
Sponsor institution
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator